| David Choi, MD | |
|
263 Farmington Avenue, Farmington, CT 06030 | |
| (860) 679-8080 | |
| (860) 679-0131 |
| Full Name | David Choi |
|---|---|
| Gender | Male |
| Speciality | Neurological Surgery |
| Location | 263 Farmington Avenue, Farmington, Connecticut |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1730409541 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207T00000X | Neurological Surgery | MD15817 (Rhode Island) | Secondary |
| 207T00000X | Neurological Surgery | 059992 (Connecticut) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| David Choi, MD 263 Farmington Avenue, Farmington, CT 06030-8082 Ph: (860) 679-8080 | David Choi, MD 263 Farmington Avenue, Farmington, CT 06030 Ph: (860) 679-8080 |
News Archive
Emerging Healthcare Solutions, Inc. announced today that its newly acquired biotechnology division Celulas Genetica will submit an international patent application for the Rutherford Procedure, a revolutionary new stem-cell treatment for liver disease.
Giardia parasites - responsible for one of the world's most common gastric diseases - are able to mimic human cell functions to break apart cells in the gut and feed off them, new research has shown.
A meta-analysis of 14 air pollution studies from around the world found that exposure to high levels of air pollutants during childhood increases the likelihood of high blood pressure in children and adolescents, and their risk for high blood pressure as adults.
A common antihistamine used to treat symptoms of allergies and the common cold, called clemastine fumarate, partially reversed damage to the visual system in people with multiple sclerosis (MS) in a preliminary study released today that will be presented at the American Academy of Neurology's 68th Annual Meeting in Vancouver, Canada, April 15 to 21, 2016.
Human Genome Sciences, Inc. today announced interim results through Week 12 following the end of treatment in a Phase 2b clinical trial conducted by Novartis to evaluate the safety and efficacy of ZALBIN™ (albinterferon alfa-2b), an investigational agent, administered monthly in combination with ribavirin in 391 treatment-naive patients with genotypes 2 and 3 chronic hepatitis C virus. The primary efficacy endpoint is sustained virologic response (SVR) at Week 48 (24 weeks following the end of treatment).
› Verified 5 days ago
Mr. Ian Thomas Mcneill, Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 263 Farmington Ave, Farmington, CT 06030 Phone: 860-679-8080 Fax: 860-679-1430 | |
Mr. Brian Joseph Kelley, M.D. Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 263 Farmington Ave, Farmington, CT 06030 Phone: 860-679-8080 Fax: 860-679-1430 | |
Hilary C Onyiuke, MD Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 263 Farmington Ave, Farmington, CT 06030 Phone: 860-679-4228 Fax: 860-679-1419 | |
Michael Joseph Giordano, MD Neurological Surgery Medicare: Medicare Enrolled Practice Location: 263 Farmington Ave, Farmington, CT 06030 Phone: 860-679-4228 Fax: 860-679-1419 | |
Richard Simon, Neurological Surgery Medicare: Not Enrolled in Medicare Practice Location: 263 Farmington Ave, Farmington, CT 06030 Phone: 860-679-4228 |